In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by ...

Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

Shares of 4D Molecular Therapeutics jumped after the company shared positive results from the latest clinical trial of its 4D-150 treatment for diabetic macular edema, a diabetes-related eye condition ...

Investing.com -- 4D Molecular Therapeutics (NASDAQ: FDMT) stock rose 36% after the company announced positive 60-week results from its 4D-150 SPECTRA clinical trial in diabetic macular edema (DME) and ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

Data shared by Schneider showed that 45% of those originally assigned to the Eylea HD groups had completed dosing intervals of 20 weeks or more. At the end of the 156-week trial, 28% had an assigned ...

D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

On July 14, 2025 Fresenius filed two IPR petitions challenging Regeneron’s patents related to aflibercept. Regeneron has not asserted that ...